Drugs / Zoledronate
Zoledronate
Trials 18 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05400603 Background | Nov 2023 → Dec 2026 expected | neuroblastoma, osteosarcoma | Emory University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00213980 Comparator | Jan 2000 → Apr 2008 | breast cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05638399 Comparator | Jan 2020 → Feb 2023 | spondylolisthesis | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02739594 Comparator | Feb 2006 → Apr 2009 | plasma cell myeloma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07281586 Background | Jan 2026 → Dec 2028 expected | osteoporosis | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06059222 Comparator | Oct 2023 → Aug 2030 expected | osteoporosis | University of Aarhus | Recruiting | No outcome recorded |
| Phase 4 | NCT05655013 Comparator | May 2023 → Feb 2027 expected | postmenopausal osteoporosis | Aarhus University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04549207 Comparator | Oct 2020 → Apr 2025 overdue | breast cancer, castration-resistant prostate carcinoma | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03664687 Comparator | Oct 2018 → Apr 2020 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02721433 Comparator | Aug 2016 → Sep 2019 | breast cancer, metastatic neoplasm, prostate cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zoledronate | “Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs...” NCT06767150 ↗25“Zoledronate” NCT04549207 ↗ |
| Known as | AXS-02 | “AXS-02 (oral zoledronate)” NCT02504008 ↗ |
| Known as | zol | “zoledronate (zol)” NCT03358017 ↗ |
| Known as | Zolendronic acid | “Drug: zolendronic acid Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy” NCT01472146 ↗ |
| Action | Inhibit | “BPs are mevalonate pathway inhibitors” NCT02347163 ↗ |
| Modality | Other / unclassified | “an investigational bisphosphonate” NCT00102908 ↗ |
| Route | Intravenous | “single IV dose of zoledronate” NCT00102908 ↗ |